Document is current
Any future updates will be listed below
-
Authors
Costi, Sara
Morris, Laurel S.
Collins, Abigail
Fernandez, Nicolas F.
Patel, Manishkumar http://orcid.org/0000-0002-7949-5610
Xie, Hui
Kim-Schulze, Seunghee
Stern, Emily R.
Collins, Katherine A.
Cathomas, Flurin
Parides, Michael K.
Whitton, Alexis E. http://orcid.org/0000-0002-7944-2172
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Russo, Scott J. http://orcid.org/0000-0002-6470-1805
Murrough, James W. http://orcid.org/0000-0001-6286-1242
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R21MH109771, MH068376)
Department of Health | National Health and Medical Research Council (APP1110773)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 4 May 2021
Revised: 10 September 2021
Accepted: 4 October 2021
First Online: 5 November 2021
Competing interests
: In the past 5 years, Dr. Murrough has provided consultation services and/or served on advisory boards for Allergan, Boehreinger Ingelheim, Clexio Biosciences, Fortress Biotech, FSV7, Global Medical Education (GME), Otsuka, and Sage Therapeutics. Dr. Murrough is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders and on a patent pending for the use of ezogabine and other KCNQ channel openers to treat depression and related conditions. The Icahn School of Medicine (employer of Dr. Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine or esketamine for the treatment of depression. The Icahn School of Medicine is also named on a patent related to the use of ketamine for the treatment of PTSD. Dr. Murrough is not named on these patents and will not receive any payments. Dr. Collins is a paid independent rater for Medavante-Prophase. Dr. Costi has provided consultation services for Guidepoint. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehreinger Ingelheim, Compass Pathway, Posit Science, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes; stock options from BlackThorn Therapeutics; and funding from NIMH, Brain and Behavior Research Foundation, the Dana Foundation, and Millennium Pharmaceuticals. Dr. Pizzagalli has a financial interest in BlackThorn Therapeutics, which has licensed the copyright to the Probabilistic Reward Task through Harvard University. Dr. Pizzagalli’s interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. All the other authors report no financial relationships with commercial interests.
